M.D., Ph.D.
A nationally recognized expert in gynecologic malignancies, Edward Wenge Wang, M.D., Ph.D., is the chief of the Division of Gynecologic Oncology and an associate professor of medical oncology at City of Hope® Cancer Center Duarte. He also holds an associate professorship at the Beckman Research Institute, where he leads a lab focused on translating scientific discoveries into new cancer therapies for patients at City of Hope and beyond.
Dr. Wang received his medical degree, master’s in immunology and doctorate in tumor immunology from Harbin Medical University in China. His international research career includes roles as a visiting investigator at Osaka University Medical School in Japan, supported by the Japan Society for the Promotion of Science, and as a postdoctoral scientist at Columbia University in New York City. He has also held research positions at the University of Pennsylvania’s School of Medicine in Philadelphia and the Howard Hughes Medical Institute in Chevy Chase, Maryland.
After a brief stint as the director of projects for the Hershey Cancer Institute at Penn State University in Philadelphia, Dr. Wang completed an internship in internal medicine at Montefiore Mount Vernon Hospital in New York state and a residency at Banner University Medical Center in Tucson, Arizona. His fellowship in hematology-oncology took place at Penn State Hershey Medical College.
At City of Hope, Dr. Wang combines leading-edge science with compassionate care to provide advanced treatment for patients with gynecologic cancers. He believes in a personalized approach to care guided by the latest research and tailored to the unique needs of each patient.
His lab works to develop new cancer therapies, including immunotherapy and targeted therapy, and studies how cancer grows, spreads and becomes resistant to treatment. Dr. Wang has received numerous grants and honors for his work, including funding from the National Institutes of Health, private foundations and City of Hope’s research initiatives. He holds several patents pending for his discoveries and continues to move promising treatments toward clinical use.